Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 744

1.

Health care costs and comorbidities for patients with inclusion body myositis.

Keshishian A, Greenberg SA, Agashivala N, Baser O, Johnson K.

Curr Med Res Opin. 2018 Jun 7:1-16. doi: 10.1080/03007995.2018.1486294. [Epub ahead of print]

PMID:
29874942
2.

Clinical, Histological, and Immunohistochemical Findings in Inclusion Body Myositis.

de Camargo LV, de Carvalho MS, Shinjo SK, de Oliveira ASB, Zanoteli E.

Biomed Res Int. 2018 Jan 29;2018:5069042. doi: 10.1155/2018/5069042. eCollection 2018.

3.

Blood-flow restricted resistance training in patients with sporadic inclusion body myositis: a randomized controlled trial.

Jørgensen AN, Aagaard P, Frandsen U, Boyle E, Diederichsen LP.

Scand J Rheumatol. 2018 May 18:1-10. doi: 10.1080/03009742.2017.1423109. [Epub ahead of print]

PMID:
29775118
4.

Pattern of muscle involvement in inclusion body myositis: a sonographic study.

Albayda J, Christopher-Stine L, Bingham Iii CO, Paik JJ, Tiniakou E, Billings S, Uy OM, Burlina P.

Clin Exp Rheumatol. 2018 May 8. [Epub ahead of print]

PMID:
29745890
5.

Muscle Shear Wave Elastography in Inclusion Body Myositis: Feasibility, Reliability and Relationships with Muscle Impairments.

Bachasson D, Dubois GJR, Allenbach Y, Benveniste O, Hogrel JY.

Ultrasound Med Biol. 2018 Jul;44(7):1423-1432. doi: 10.1016/j.ultrasmedbio.2018.03.026. Epub 2018 Apr 26.

PMID:
29706410
6.

[Sporadic Inclusion Body Myositis and Autoantibodies].

Yamashita S, Ando Y.

Brain Nerve. 2018 Apr;70(4):449-457. doi: 10.11477/mf.1416201017. Japanese.

PMID:
29632292
7.

New Developments in the Genetics of Inclusion Body Myositis.

Britson KA, Yang SY, Lloyd TE.

Curr Rheumatol Rep. 2018 Apr 2;20(5):26. doi: 10.1007/s11926-018-0738-0. Review.

PMID:
29611059
8.

A Patient with HCV Infection and a Sustained Virological Response to Direct-acting Antiviral Treatment who Developed Inclusion Body Myositis.

Kuwano T, Akuta N, Suzuki F, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Saitoh S, Kobayashi M, Suzuki Y, Kobayashi M, Arase Y, Ikeda K, Kumada H.

Intern Med. 2018 Mar 30. doi: 10.2169/internalmedicine.0585-17. [Epub ahead of print]

9.

Sporadic inclusion body myositis: magnetic resonance imaging and ultrasound characteristics.

Tsukita K, Yagita K, Sakamaki-Tsukita H, Suenaga T.

QJM. 2018 Mar 22. doi: 10.1093/qjmed/hcy065. [Epub ahead of print] No abstract available.

PMID:
29579291
10.

Rapamycin for inclusion body myositis: targeting non-inflammatory mechanisms.

Lilleker JB, Bukhari M, Chinoy H.

Rheumatology (Oxford). 2018 Feb 26. doi: 10.1093/rheumatology/key043. [Epub ahead of print] No abstract available.

PMID:
29529264
11.

Electromyographic findings in sporadic inclusion body myositis.

Nojszewska M, Gawel M, Kierdaszuk B, Sierdziński J, Szmidt-Sałkowska E, Seroka A, Kamińska AM, Kostera-Pruszczyk A.

J Electromyogr Kinesiol. 2018 Apr;39:114-119. doi: 10.1016/j.jelekin.2018.02.003. Epub 2018 Feb 11.

PMID:
29482084
12.

Inclusion body myositis and human immunodeficiency virus type 1: A new case report and literature review.

Couture P, Malfatti E, Morau G, Mathian A, Cohen-Aubart F, Nielly H, Amoura Z, Cherin P.

Neuromuscul Disord. 2018 Apr;28(4):334-338. doi: 10.1016/j.nmd.2018.01.005. Epub 2018 Jan 10.

PMID:
29426734
13.

Cytokine Profiling of Serum Allows Monitoring of Disease Progression in Inclusion Body Myositis.

Badrising UA, Tsonaka R, Hiller M, Niks EH, Evangelista T, Lochmüller H, Verschuuren JJ, Aartsma-Rus A, Spitali P.

J Neuromuscul Dis. 2017;4(4):327-335. doi: 10.3233/JND-170234.

PMID:
29172005
14.

Five-year history of dysphagia as a sole initial symptom in inclusion body myositis.

Shibata S, Izumi R, Hara T, Ohshima R, Nakamura N, Suzuki N, Kato K, Katori Y, Tateyama M, Kuroda H, Aoki M.

J Neurol Sci. 2017 Oct 15;381:325-327. doi: 10.1016/j.jns.2017.09.014. Epub 2017 Sep 12. No abstract available.

PMID:
28991709
15.

Sporadic Inclusion Body Myositis: MRI Findings and Correlation With Clinical and Functional Parameters.

Guimaraes JB, Zanoteli E, Link TM, de Camargo LV, Facchetti L, Nardo L, Fernandes ADRC.

AJR Am J Roentgenol. 2017 Dec;209(6):1340-1347. doi: 10.2214/AJR.17.17849. Epub 2017 Sep 27.

PMID:
28952813
16.

Unfounded Claims of Improved Functional Outcomes Attributed to Follistatin Gene Therapy in Inclusion Body Myositis.

Greenberg SA.

Mol Ther. 2017 Oct 4;25(10):2235-2237. doi: 10.1016/j.ymthe.2017.09.002. Epub 2017 Sep 8. No abstract available.

PMID:
28927986
17.

Botulinum toxin alleviates dysphagia of patients with inclusion body myositis.

Schrey A, Airas L, Jokela M, Pulkkinen J.

J Neurol Sci. 2017 Sep 15;380:142-147. doi: 10.1016/j.jns.2017.07.031. Epub 2017 Jul 24.

PMID:
28870555
18.

Concomitant occurrence of FXTAS and clinically defined sporadic inclusion body myositis: report of two cases.

Lechpammer M, Martínez Cerdeńo V, Hunsaker MR, Hah M, Gonzales H, Tisch S, Joffe R, Pamphlett R, Tassone F, Hagerman PJ, Bolitho SJ, Hagerman RJ.

Croat Med J. 2017 Aug 31;58(4):310-315.

19.

Inclusion body myositis: advancements in diagnosis, pathomechanisms, and treatment.

Schmidt K, Schmidt J.

Curr Opin Rheumatol. 2017 Nov;29(6):632-638. doi: 10.1097/BOR.0000000000000436. Review.

PMID:
28832349
20.

Transcriptional profiling identifies differential expression of long non-coding RNAs in Jo-1 associated and inclusion body myositis.

Hamann PD, Roux BT, Heward JA, Love S, McHugh NJ, Jones SW, Lindsay MA.

Sci Rep. 2017 Aug 14;7(1):8024. doi: 10.1038/s41598-017-08603-9.

Supplemental Content

Loading ...
Support Center